EyePoint Pharmaceuticals (NASDAQ:EYPT) Given New $33.00 Price Target at Chardan Capital

EyePoint Pharmaceuticals (NASDAQ:EYPT) had its price target increased by Chardan Capital from $28.00 to $33.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other brokerages have also issued reports on EYPT. JPMorgan Chase & Co. reduced their target price on EyePoint Pharmaceuticals from $32.00 to $29.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of EyePoint Pharmaceuticals in a report on Friday, October 25th. Jefferies Financial Group started coverage on EyePoint Pharmaceuticals in a report on Wednesday, August 28th. They set a “buy” rating and a $15.00 target price on the stock. StockNews.com upgraded EyePoint Pharmaceuticals to a “sell” rating in a report on Saturday, September 21st. Finally, Scotiabank assumed coverage on EyePoint Pharmaceuticals in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $18.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $29.63.

EyePoint Pharmaceuticals Trading Up 0.3 %

Shares of NASDAQ EYPT traded up $0.04 during midday trading on Friday, hitting $11.63. The company’s stock had a trading volume of 537,131 shares, compared to its average volume of 940,403. The business’s 50 day moving average is $9.50 and its two-hundred day moving average is $10.07. EyePoint Pharmaceuticals has a 12-month low of $5.86 and a 12-month high of $30.99. The firm has a market cap of $622.41 million, a P/E ratio of -5.82 and a beta of 1.50.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.03). The firm had revenue of $9.48 million for the quarter, compared to analysts’ expectations of $11.61 million. EyePoint Pharmaceuticals had a negative return on equity of 43.24% and a negative net margin of 172.29%. On average, analysts predict that EyePoint Pharmaceuticals will post -2.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Ameritas Investment Partners Inc. boosted its position in EyePoint Pharmaceuticals by 44.0% during the first quarter. Ameritas Investment Partners Inc. now owns 3,719 shares of the company’s stock worth $77,000 after acquiring an additional 1,136 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of EyePoint Pharmaceuticals by 68.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock valued at $82,000 after purchasing an additional 4,172 shares during the last quarter. Greenwich Wealth Management LLC boosted its holdings in shares of EyePoint Pharmaceuticals by 8.3% in the 3rd quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company’s stock valued at $93,000 after purchasing an additional 900 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of EyePoint Pharmaceuticals by 271.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company’s stock valued at $95,000 after acquiring an additional 7,953 shares during the period. Finally, Cyndeo Wealth Partners LLC purchased a new position in shares of EyePoint Pharmaceuticals in the 3rd quarter valued at $100,000. 99.41% of the stock is owned by hedge funds and other institutional investors.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.